Merck, known as MSD outside the United States and Canada, has completed the acquisition of Terns Pharmaceuticals.

默克公司（在美国和加拿大以外地区称为MSD）已经完成了对Terns Pharmaceuticals的收购。

The deal reflects Merck’s continued focus on strengthening its research-led pipeline and advancing innovative treatments. A key asset in the acquisition is TERN-701, an investigational therapy being developed for certain patients with chronic myeloid leukaemia (CML).

该交易反映了默克公司继续专注于加强其研究导向的产品线并推进创新治疗。此次收购的一项关键资产是TERN-701，这是一种正在为某些慢性髓性白血病（CML）患者开发的在研疗法。

TERN-701 has received Breakthrough Therapy Designation from the US Food and Drug Administration for the treatment of adults with Philadelphia chromosome-positive CML in the chronic phase who do not have the T315I mutation and have previously been treated with two or more tyrosine kinase inhibitors. The designation is supported by data from the ongoing Phase 1/2 CARDINAL trial..

TERN-701已获得美国食品药品监督管理局（FDA）的突破性疗法认定，用于治疗未携带T315I突变且既往接受过两种或以上酪氨酸激酶抑制剂治疗的费城染色体阳性慢性髓性白血病（CML）慢性期成人患者。该认定得到了正在进行的1/2期CARDINAL试验数据的支持。

Under the terms of the transaction, Merck acquired all outstanding shares of Terns through a cash tender offer at a price of $53.00 per share, subject to applicable tax adjustments. The offer resulted in the acquisition of approximately 86.36% of Terns’ outstanding shares. This was followed by a merger process through which Terns became a wholly owned subsidiary of Merck.

根据交易条款，默克公司通过现金要约收购了Terns所有已发行股份，每股价格为53.00美元，并需根据适用的税务调整进行调整。该要约导致默克公司收购了Terns大约86.36%的已发行股份。随后，通过合并程序，Terns成为默克公司的全资子公司。

As a result, Terns’ shares will no longer be listed on the Nasdaq Global Select Market..

因此，Terns的股票将不再在纳斯达克全球精选市场上市。

The transaction is expected to be treated as an asset acquisition. Merck anticipates recording a charge of around $5.8 billion to research and development expenses in its 2026 financial results. The deal is also expected to have a negative impact on earnings per share of about $0.12 in 2026, mainly due to development and financing costs related to TERN-701..

该交易预计将被视为一项资产收购。默克预计将在其2026年财务业绩中记录约58亿美元的研发费用支出。这笔交易预计还将对2026年每股收益产生约0.12美元的负面影响，主要原因是与TERN-701相关的开发和融资成本。

TERN-701 is an oral investigational therapy designed to target the BCR::ABL1 protein through an allosteric mechanism, with the aim of improving treatment outcomes for patients with chronic myeloid leukaemia.

TERN-701 是一种口服研究性疗法，旨在通过变构机制靶向 BCR::ABL1 蛋白，以期改善慢性髓性白血病患者的治疗效果。

Source: businesswire.com

来源：businesswire.com